PharmaEngine (4162) - Total Liabilities
Based on the latest financial reports, PharmaEngine (4162) has total liabilities worth NT$112.86 Million TWD (≈ $3.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaEngine - Total Liabilities Trend (2009–2024)
This chart illustrates how PharmaEngine's total liabilities have evolved over time, based on quarterly financial data. See PharmaEngine current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
PharmaEngine Competitors by Total Liabilities
The table below lists competitors of PharmaEngine ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aldel Financial II Inc. Class A Ordinary Shares
NASDAQ:ALDF
|
USA | $57.00 |
|
E-Lead Electronic Co Ltd
TW:2497
|
Taiwan | NT$2.95 Billion |
|
Deutsche Real Estate AG
F:DRE2
|
Germany | €97.69 Million |
|
Praetorian Acquisition Corp. Class A Ordinary Shares
NASDAQ:PTOR
|
USA | $50.14K |
|
Berry Petroleum Corp
NASDAQ:BRY
|
USA | $748.02 Million |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
Turkey | TL168.59 Million |
|
AGILYX ASA NK -02
F:5NQ
|
Germany | €76.24 Million |
|
EUWAX Aktiengesellschaft
F:EUX
|
Germany | €134.28 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down PharmaEngine's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PharmaEngine market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 43.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaEngine's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaEngine (2009–2024)
The table below shows the annual total liabilities of PharmaEngine from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$448.01 Million ≈ $14.11 Million |
+392.29% |
| 2023-12-31 | NT$91.01 Million ≈ $2.87 Million |
-3.66% |
| 2022-12-31 | NT$94.47 Million ≈ $2.98 Million |
+7.71% |
| 2021-12-31 | NT$87.70 Million ≈ $2.76 Million |
-55.20% |
| 2020-12-31 | NT$195.78 Million ≈ $6.17 Million |
+22.06% |
| 2019-12-31 | NT$160.40 Million ≈ $5.05 Million |
+5.06% |
| 2018-12-31 | NT$152.67 Million ≈ $4.81 Million |
-23.63% |
| 2017-12-31 | NT$199.90 Million ≈ $6.30 Million |
+24.56% |
| 2016-12-31 | NT$160.48 Million ≈ $5.06 Million |
+102.09% |
| 2015-12-31 | NT$79.41 Million ≈ $2.50 Million |
+340.73% |
| 2014-12-31 | NT$18.02 Million ≈ $567.67K |
-30.44% |
| 2013-12-31 | NT$25.90 Million ≈ $816.09K |
+82.39% |
| 2012-12-31 | NT$14.20 Million ≈ $447.44K |
-8.90% |
| 2011-12-31 | NT$15.59 Million ≈ $491.17K |
+12.60% |
| 2010-12-31 | NT$13.85 Million ≈ $436.19K |
-54.60% |
| 2009-12-31 | NT$30.50 Million ≈ $960.76K |
-- |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more